Embryonic Stem Cell Research Career Enhancement

说明：请参阅说明。说明应用程序的广泛、长期目标和具体目标，并参考与健康相关的 项目(即与该机构使命的相关性)。简明扼要地描述实现这些目标的研究设计和方法。描述 你将用来追求这些目标的基本原理和技术。 此外，用两三句简单明了的话描述这项研究与公共卫生的相关性。如果应用程序得到资助，则此 原样的描述将成为公开信息。因此，不包括专有/机密信息。不要超过空格 但前提是。 这是一份K18助学金的补充申请。这项补充的目的是提供资金给 允许在我的实验室启动胚胎干细胞研究，以取代在 我的K18拨款支持的研究在澳大利亚进行，这些研究已无法转移到我的 由于我的研究导师(马丁·佩拉博士)无法控制的不可预见的情况而流产，我的 佩拉实验室的合作者(Ernst Wolvetang博士)，或我。有了这个补充支持，我的实验室将能够 购买3个美国联邦批准的人类胚胎干细胞(HESC)系，慢病毒表达 转导胚胎干细胞的载体和寡核苷酸(加上测序确认) 表达载体的构建。这些资金将使我们能够继续发展hESC系列产品，并 用慢病毒表达载体转导这些hESC细胞。一旦我们完成了这些步骤，我们将 已经重建了我们在澳大利亚创造的东西，并将准备启动我们自己的研究计划 关于hESC的严肃性和分化的调节。 演出现场(S)(组织、市、州) H·李·莫菲特癌症中心和研究所 南佛罗里达大学 佛罗里达州坦帕市 小灵通398(04/06版)第2页表格第2页 首席调查员/项目主任(最后、第一、中间)：ZllCkerman，Kenneth S. 关键人员。请参阅说明。根据需要使用续页以如下所示的格式提供所需信息。 从首席调查员(S)开始。按字母顺序列出所有其他关键人员，姓氏在前。 名称时代共享用户名项目上的组织角色 首页--期刊主要分类--期刊细介绍--期刊题录与文摘--期刊详细文摘内容 其他重要贡献者 命名项目中的组织角色 人类胚胎干细胞Q否^是 如果建议的项目涉及人类胚胎干细胞，请从下面的列表中列出特定细胞系(S)的注册号： Http://StemcellS.nih.qov/registrv/index.asp.根据需要使用二次评估页面。 如果此时不能引用特定行，则包括一条声明，说明将使用注册表中的一行。 细胞系 WA01 WA07 WA09 小灵通398(04/06版)第3页表格第2页-续 从头到尾连续地给下面的页面编号 应用程序。不要使用诸如4a、4b之类的后缀。 首席调查员/项目主任(最后、第一、中间)：ZllCkerman，Kenneth S. 必须在每张打印页和每张续页的顶部提供首席调查员/项目主任的姓名。 研究补助金 CONTENTS表 页码 正面第1页 描述、绩效地点、关键人员、其他重要贡献者和人员 胚胎干细胞2-3

DESCRIPTION: See instructions. State the application's broad, long-term objectives and specific aims, making referenceto the health relatedness of the project (i.e., relevance to the mission of the agency). Describe concisely the research design and methods for achieving these goals. Describe the rationale and techniques you will use to pursue these goals. In addition, in two or three sentences, describe in plain, lay language the relevance of this research to public health. If the application is funded, this description, as is, will become public information. Therefore, do not include proprietary/confidential information. DO NOT EXCEED THE SPACE PROVIDED. This is an application for a supplement to a K18 grant. The purpose of the supplement is to provide funds to permit initiation of embryonic stem cell research in my laboratory to replace the reagents generated during my K18 grant-supported research Waningin Australia, which have become unavailable for transfer to my aboratory due to unforeseen circumstances beyond the control of my research mentor (Dr. Martin Pera), my collaborator in the Pera lab (Dr. Ernst Wolvetang), or me. With this supplemental support, my lab will be able to purchase 3 human US federally approved human embryonic stem cell (hESC) lines, lentiviral expression vectors to transduce the embryonic stem cells, and oligonucleotides (plus sequencing confirmation) for construction of expression vectors. These funds will allow us to extablish growth of hESC lines and to transduce these hESC lines with lentiviral expression vectors. Once we have completed these steps, we will have reconstructed what we created in Australia and will be prepared to initiate our own research program on regulation of hESC sternness and differentiation. PERFORMANCE SITE(S) (organization, city, state) H. Lee Moffitt Cancer Center and Research Institute University of South Florida Tampa, FL PHS 398 (Rev. 04/06) Page 2 Form Page 2 Principal Investigator/Program Director (Last, First, Middle): ZllCkerman, Kenneth S. KEY PERSONNEL. See instructions. Use continuation pages as neededto provide the required information in the formatshown below. Start with Principal Investigator(s).List all other key personnel in alphabetical order, last name first. Name eRA Commons User Name Organization Role on Project Kenneth S. Zuckerman kenzuckerman H. Lee Moffitt Cancer CtrP.I. OTHER SIGNIFICANT CONTRIBUTORS Name Organization Role on Project Human Embryonic Stem Cells Q No ^ Yes If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the following list: http://StemcellS.nih.qov/registrv/index.asp. Usecontinuation pages as needed. If a specific line cannot be referenced at this time,include a statementthat one from the Registry will be used. Cell Line WA01 WA07 WA09 PHS 398 (Rev. 04/06) Page 3 Form Page 2-continued Number the following pages consecutively throughout the application. Do not use suffixes such as 4a, 4b. Principal Investigator/Program Director (Last, First, Middle): ZllCkerman, Kenneth S. The name of the principal investigator/program director must be provided at the top of each printed page and each continuation page. RESEARCH GRANT TABLE OFCONTENTS Page Numbers Face Page 1 Description, Performance Sites, Key Personnel, Other Significant Contributors, and Human Embryonic Stem Cells 2-3